Amneal Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(unaudited; in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net revenue | $784,513 | $702,468 | $2,204,441 | $2,063,439 |
| Cost of goods sold | 510,539 | 432,910 | 1,388,323 | 1,305,874 |
| Gross profit | 273,974 | 269,558 | 816,118 | 757,565 |
| Selling, general and administrative | 137,815 | 118,692 | 380,369 | 347,749 |
| Research and development | 63,352 | 61,097 | 151,356 | 136,449 |
| Intellectual property legal development expenses | 2,437 | 1,967 | 6,221 | 3,993 |
| Restructuring and other charges | 143 | 172 | 1,738 | 1,862 |
| (Credit) charges related to legal matters, net | — | (149) | (390) | 94,909 |
| Other operating income | (117) | (1,030) | (5,239) | (930) |
| Operating income | 70,344 | 88,809 | 282,063 | 173,533 |
| Other (expense) income: | ||||
| Interest expense, net | (62,814) | (65,511) | (184,854) | (196,933) |
| Foreign exchange (loss) gain, net | (3,431) | 2,274 | 9,072 | 815 |
| Decrease (increase) in tax receivable agreement liability | 20,808 | (11,327) | 5,701 | (26,719) |
| Loss on refinancing | (31,365) | — | (31,365) | — |
| Other income, net | 1,235 | 1,178 | 3,357 | 9,610 |
| Total other expense, net | (75,567) | (73,386) | (198,089) | (213,227) |
| Income (loss) before income taxes | (5,223) | 15,423 | 83,974 | (39,694) |
| (Benefit from) provision for income taxes | (23,355) | 3,666 | 5,614 | 13,440 |
| Net income (loss) | 18,132 | 11,757 | 78,360 | (53,134) |
| Less: Net income attributable to non-controlling interests | (15,763) | (11,913) | (41,379) | (32,671) |
| Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | $2,369 | $(156) | $36,981 | $(85,805) |
| Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: | ||||
| Basic | $0.01 | $(—) | $0.12 | $(0.28) |
| Diluted | $0.01 | $(—) | $0.11 | $(0.28) |
| Weighted-average common shares outstanding: | ||||
| Basic | 314,168 | 309,647 | 312,998 | 308,685 |
| Diluted | 324,754 | 309,647 | 323,704 | 308,685 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.